ArticleThe Journal of clinical investigation2018
Endothelial chimerism and vascular sequestration protect pancreatic islet grafts from antibody-mediated rejection.
Article in The Journal of clinical investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Dual inhibition of mTOR and calcineurin pathways mitigates missing self-induced NK cell-mediated microvascular rejection.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Impact of preformed donor-specific anti-HLA antibodies on pancreatic islet transplantation outcomes: do they matter as they do in solid organ transplantation?Frontiers in immunology · 2026Review
- Sensitization in Transplantation Assessment of Risk 2025 innate working group: The potential role of innate allorecognition in kidney allograft damage.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025Review
- Chemotaxis overrides the killing response in alloreactive CTLs, providing vascular immune privilege during cellular rejection.The Journal of clinical investigation · 2025Article
- Article
- Occlusion of TCR binding to HLA-A*11:01 by a non-pathogenic human alloantibody.Cellular and molecular life sciences : CMLS · 2025Article
- γδ T Cells' Role in Donor-Specific Antibody Generation: Insights From Transplant Recipients and Experimental Models.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Allogeneic Islet Transplantation: Chronicle of a Death Foretold?Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Natural killer cell-mediated innate microvascular rejection.Nature reviews. Nephrology · 2024Article
- European Consensus on the Management of Sensitized Kidney Transplant Recipients: A Delphi Study.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Allorecognition Unveiled: Integrating Recent Breakthroughs Into the Current Paradigm.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Transcriptional and spatial profiling of the kidney allograft unravels a central role for FcyRIII+ innate immune cells in rejection.Nature communications · 2023Article
- Review
- Endothelial cell provenance: an unclear role in transplant medicine.Frontiers in transplantation · 2023Review
- Chronic Pancreas Allograft Rejection Followed by Successful HLA-Incompatible Islet Alloautotransplantation: A Novel Strategy?Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- A bibliometric and knowledge-map analysis of antibody-mediated rejection in kidney transplantation.Renal failure · 2023Article
- Allo Beta Cell transplantation: specific features, unanswered questions, and immunological challenge.Frontiers in immunology · 2023Review
- The challenge of HLA donor specific antibodies in the management of pancreatic islet transplantation: an illustrative case-series.Scientific reports · 2022Observational
- Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.The Journal of experimental medicine · 2021Article
- Generation of vascular chimerism within donor organs.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Humoral rejection is the most common cause of solid organ transplant failure. Here, we evaluated a cohort of 49 patients who were successfully grafted with allogenic islets and determined that the appearance of donor-specific anti-HLA antibodies (DSAs) did not accelerate the rate of islet graft attrition, suggesting resistance to humoral rejection. Murine DSAs bound to allogeneic targets expressed by islet cells and induced their destruction in vitro; however, passive transfer of the same DSAs did not affect islet graft survival in murine models. Live imaging revealed that DSAs were sequestrated in the circulation of the recipients and failed to reach the endocrine cells of grafted islets. We used murine heart transplantation models to confirm that endothelial cells were the only accessible targets for DSAs, which induced the development of typical microvascular lesions in allogeneic transplants. In contrast, the vasculature of DSA-exposed allogeneic islet grafts was devoid of lesions because sprouting of recipient capillaries reestablished blood flow in grafted islets. Thus, we conclude that endothelial chimerism combined with vascular sequestration of DSAs protects islet grafts from humoral rejection. The reduced immunoglobulin concentrations in the interstitial tissue, confirmed in patients, may have important implications for biotherapies such as vaccines and monoclonal antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.